Therapeutic area

Nephrology

Glomerulonephritis, chronic kidney disease, polycystic kidney disease, and renal metabolic conditions.

Core & active disease programs

Chronic Kidney Disease

$646.5B+ attributable cost

$50.3B$+ drug spend

97 assets · 2 indications

Provisional & emerging programs (11)Early clinical pipeline & single-asset indications

IgA Nephropathy

Primary Membranous Nephropathy

APOL1-Mediated Kidney Disease

Autosomal Dominant Polycystic Kidney Disease

Complement-Mediated Renal Disease

Focal Segmental Glomerulosclerosis

Glomerular Disease

Hemodialysis Access

Hyperphosphatemia

Kidney Transplant Rejection

Lupus Nephritis

All assets in Nephrology